CEREVEL THERAPEUTICS HOLDING (CERE) Stock Price, Quote, News and Overview
NASDAQ:CERE - Nasdaq - US15678U1280 - Common Stock - Currency: USD
CERE Quote, Performance and Key Statistics
44.96
+0.33 (+0.74%)
The current stock price of CERE is 44.96 USD. In the past month the price increased by 9.05%. In the past year, price increased by 100.09%.
CERE Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About CERE
Company Profile
Cerevel Therapeutics Holdings, Inc. engages in the discovery and development of new therapies for neuroscience diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 355 full-time employees. The company went IPO on 2020-06-05. The firm is focused on neuroscience that combines an understanding of disease-related biology and neurocircuitry of the brain with advanced chemistry and central nervous system (CNS) target receptor selective pharmacology to discover and design new therapies. The company focuses on transform the lives of patients through the development of new therapies for neuroscience diseases, including schizophrenia, Alzheimer’s disease psychosis, epilepsy, panic disorder and Parkinson’s disease. Its pipeline candidates include Emraclidine, Darigabat, Tavapadon and CVL-871. Emraclidine is a positive allosteric modulator (PAM), that selectively targets the muscarinic acetylcholine 4 receptor subtype (M4). Darigabat is a PAM that selectively targets the alpha 2/3/5 subunits of the GABAA receptor. Tavapadon is a selective dopamine D1/D5 receptor partial agonist that it is developing for the treatment of Parkinson’s disease.
Company Info
CEREVEL THERAPEUTICS HOLDING
222 Jacobs Street, Suite 200
Cambridge MASSACHUSETTS 02116 US
CEO: N. Anthony Coles
Employees: 355
Company Website: https://www.cerevel.com/
Phone: 18443042048
CEREVEL THERAPEUTICS HOLDING / CERE FAQ
What is the stock price of CEREVEL THERAPEUTICS HOLDING today?
The current stock price of CERE is 44.96 USD. The price increased by 0.74% in the last trading session.
What is the ticker symbol for CEREVEL THERAPEUTICS HOLDING stock?
The exchange symbol of CEREVEL THERAPEUTICS HOLDING is CERE and it is listed on the Nasdaq exchange.
On which exchange is CERE stock listed?
CERE stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for CEREVEL THERAPEUTICS HOLDING stock?
14 analysts have analysed CERE and the average price target is 44.27 USD. This implies a price decrease of -1.54% is expected in the next year compared to the current price of 44.96. Check the CEREVEL THERAPEUTICS HOLDING stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is CEREVEL THERAPEUTICS HOLDING worth?
CEREVEL THERAPEUTICS HOLDING (CERE) has a market capitalization of 8.19B USD. This makes CERE a Mid Cap stock.
How many employees does CEREVEL THERAPEUTICS HOLDING have?
CEREVEL THERAPEUTICS HOLDING (CERE) currently has 355 employees.
What are the support and resistance levels for CEREVEL THERAPEUTICS HOLDING (CERE) stock?
CEREVEL THERAPEUTICS HOLDING (CERE) has a support level at 42.53. Check the full technical report for a detailed analysis of CERE support and resistance levels.
Should I buy CEREVEL THERAPEUTICS HOLDING (CERE) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of CERE, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of CERE, evaluating the profitability, health, valuation and growth aspects
- CEREVEL THERAPEUTICS HOLDING (CERE) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- CEREVEL THERAPEUTICS HOLDING (CERE) Sales and EPS estimates to see what analysts future expectations are.
- CEREVEL THERAPEUTICS HOLDING (CERE) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- CEREVEL THERAPEUTICS HOLDING (CERE) Insider and Institutional Ownership to learn about the owners and their transactions.
- CEREVEL THERAPEUTICS HOLDING (CERE) Stock Chart to make your own analysis
- CEREVEL THERAPEUTICS HOLDING (CERE) Latest news and press-releases to stay up to date.
Does CEREVEL THERAPEUTICS HOLDING (CERE) stock pay dividends?
CERE does not pay a dividend.
When does CEREVEL THERAPEUTICS HOLDING (CERE) report earnings?
CEREVEL THERAPEUTICS HOLDING (CERE) will report earnings on 2024-10-30, before the market open.
What is the Price/Earnings (PE) ratio of CEREVEL THERAPEUTICS HOLDING (CERE)?
CEREVEL THERAPEUTICS HOLDING (CERE) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.73).
CERE Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to CERE. When comparing the yearly performance of all stocks, CERE is one of the better performing stocks in the market, outperforming 96.77% of all stocks.
CERE Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to CERE. While CERE seems to be doing ok healthwise, there are quite some concerns on its profitability.
CERE Financial Highlights
Over the last trailing twelve months CERE reported a non-GAAP Earnings per Share(EPS) of -2.73. The EPS decreased by -7.48% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -40.85% | ||
| ROE | -81.58% | ||
| Debt/Equity | 0.6 |
CERE Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 53% to CERE. The Buy consensus is the average rating of analysts ratings from 14 analysts.